Gaetano Morello, ND | Chairman of the Advisory Board
Gaetano Morello, ND, Chairman of the Advisory Board, is a practicing physician at the Complex Chronic Disease Program at the Woman’s Hospital in BC, a member of the Quality Assurance Committee for the College of Naturopathic Physicians of BC, and founding CEO of Enzymatic Therapy Canada Inc., which was the first company to introduce standardized extracts in Canada.
Alasdair Barr, PhD
Alasdair Barr, PhD, is Professor at the University of British Columbia with a focus on mental health and addictions research, using multidisciplinary and translational approach that spans from laboratory to clinic. Dr. Barr maintains active programs in both clinical and preclinical research.
Caroline MacCallum, MD, FRCPC, BSc Pharmacy
Caroline MacCallum, MD, FRCPC, BSc Pharmacy, is an internal medicine specialist with training in complex pain, addiction medicine, and cannabinoid medicine. She is a clinical instructor in the Department of Medicine at the University of British Columbia (UBC), a guest lecturer and preceptor for UBC Faculty of Pharmaceutical Sciences Program.
Eduardo Muñoz, MD, PhD
Eduardo Muñoz, MD, PhD, is Professor of Immunology at the University of Córdoba (Spain), a member of the editorial board of several scientific journals, an expert in the study of cannabinoids and endocannabinoids, and co-founder of VivaCell Biotechnology and Glactone Pharma AB.
Giovanni Appendino, PhD
Giovanni Appendino, PhD, is Professor of Organic Chemistry at the University of Eastern Piedmont, Novara (Italy), Editor in Chief of the scientific journal Fitoterapia, and an expert in the chemistry and medicinal chemistry of cannabinoids.
James T. McCracken, MD
James T. McCracken, MD, is the Joseph Campbell Professor of Child Psychiatry, and Director of the Division of Child and Adolescent Psychiatry at the David Geffen School of Medicine at UCLA. An active clinician who has been included in America’s Top Doctors, Best Doctors and SuperDoctors listings for more than a decade, Dr. McCracken is an expert in child psychiatry and serves on the editorial board of the journal Molecular Autism.
Jim DeMesa, MD, MBA
Jim DeMesa, MD, MBA, is CEO of Emerald Health Pharmaceuticals (a subsidiary of Emerald Health Sciences Inc., the Company’s largest shareholder) with 28-years’ experience in pharmaceutical product development, co-founder of MedXcel, a medical education company, member of the Boards of Directors of OncoSec Medical and Induce Biologics, and a former practicing physician.
Stefan Meyer is co-founder and Managing Director of Phytoplant Research S.L of Córdoba (Spain), a company that specializes in developing the industrial chain of medicinal plants. Mr. Meyer has extensive experience in international marketing and strategy development.